Long COVID as a Disease of Accelerated Biological Aging: An Opportunity to Translate Geroscience Interventions
Ageing Research Reviews,
Год журнала:
2024,
Номер
99, С. 102400 - 102400
Опубликована: Июнь 28, 2024
Язык: Английский
Ultra-Low-Dose Inhalation of Melphalan as an Additional Treatment for COVID-19-Associated Pneumonia
Journal of Clinical Medicine,
Год журнала:
2025,
Номер
14(7), С. 2149 - 2149
Опубликована: Март 21, 2025
Background/Objectives:
Effective
anti-inflammatory
treatment
for
COVID-19
is
necessary.
It
was
shown
that
ultra-low
doses
(100-fold
lower
than
therapeutic
ones)
of
alkylating
drug
melphalan
(MEL)
interact
with
cytokine
cell
receptors
without
DNA
damage.
A
method
treating
severe
MEL
inhalations
proposed.
The
objective
to
study
the
efficacy
and
safety
pneumonia
treatment.
Methods:
An
open-label
comparative
(NCT04380376)
120
patients
divided
into
two
groups
conducted.
control
group
(CG)
received
standard
treatment,
(MG)
also
seven
daily
0.1
mg
inhalations.
Changes
in
clinical
improvement,
inflammatory
markers,
CT
lung
scan
data
were
primary
secondary
endpoints.
Results:
Patients
MG
showed
significantly
better
outcomes
compared
CG,
improvements
dyspnea
according
WHO
Ordinal
Scale
Clinical
Improvement
modified
Borg
Scale,
scans,
markers.
No
adverse
effects
(including
irritant
bronchoconstrictor
effects)
possibly
related
reported.
Conclusions:
This
demonstrated
incorporating
ultra-low-dose
regimen
COVID-19-associated
pneumonia.
conclusion
supported
by
a
statistically
significant
improvement
outcomes,
as
assessed
OSCI,
more
rapid
reduction
severity
dyspnea,
marked
effect,
evidenced
faster
decline
C-reactive
protein
levels.
observed
proposed
method.
Further
large-scale
randomized
trials
are
warranted
validate
these
findings
evaluate
potential
implementation
inhalation
practice.
Язык: Английский
One-year post-acute COVID-19 syndrome and mortality in South Korea: a nationwide matched cohort study using claims data
Frontiers in Public Health,
Год журнала:
2024,
Номер
12
Опубликована: Июль 10, 2024
Background
Current
understanding
of
post-COVID-19
syndrome
in
South
Korea
is
primarily
based
on
survey
studies
or
research
targeting
specific
patient
groups,
such
as
those
hospitalized.
Moreover,
the
majority
relevant
have
been
conducted
European
and
North
American
populations,
which
may
limit
their
applicability
to
Korean
context.
To
address
this
gap,
our
study
explores
one-year
outcomes
COVID-19,
focusing
potential
post-acute
all-cause
mortality
Korea.
Methods
This
retrospective
cohort
used
nationwide
claims
data
Korea,
including
adults
aged
>18
with
records
between
January
20,
2020,
February
25,
2021.
Patients
were
classified
into
COVID-19
non-COVID-19
groups
matched
1:1
propensity
scores.
Primary
12-month
mortality.
Results
The
involved
34,802
patients.
group
had
significantly
elevated
risks
coagulopathies
(OR
=
2.70
[2.24,
3.28];
p
<
0.001),
chronic
lower
respiratory
diseases
1.96
[1.80,
2.14];
symptoms
circulatory
systems
1.91
2.04];
mood
disorders
1.67
[1.51,
1.86];
cardiac
1.39
[1.21,
1.59];
cognition,
perception,
emotional
state,
behavior
1.15
[1.04,
1.27];
0.005).
All-cause
was
higher
during
6
months
1.34
[1.06,
1.69];
0.015),
but
gradually
decreased,
reaching
an
OR
0.996
([0.83,
1.19];
0.964)
at
1
year.
Conclusion
In
includes
coagulopathies,
issues,
disorders,
diseases.
risk
heightened
for
up
months,
then
decreases
resolves
within
a
Язык: Английский